2.50
Hdl Handle:
http://hdl.handle.net/10541/109472
Title:
The Christie Hospital adjuvant tamoxifen trial.
Authors:
Ribeiro, G; Swindell, Ric
Abstract:
A clinical trial was carried out at The Christie Hospital, Manchester, England, between November 1976 and June 1982. Following surgery, patients with clinical stage T1-T3a, N1-N2b, M0 tumors were randomly allocated in the following way: premenopausal women to either tamoxifen 20 mg/day for 1 year or to an irradiation-induced menopause; postmenopausal women to either tamoxifen for 1 year or no further treatment (controls). In the node-negative subgroup, an analysis at a median follow-up of 10 years shows no statistically significant difference in overall or disease-free survival between tamoxifen-treated patients and irradiation-induced menopause and control patients. Side effects were few, and compliance was excellent. There was no significant increase of second primary tumors in target endocrine organs in the tamoxifen-treated patients. For the whole series of 961 patients, a log-rank analysis of events, allowing for node status, still shows a statistically significant benefit for tamoxifen-treated patients (P = .04).
Affiliation:
Department of Radiotherapy, Christie Hospital, Holt Radium Institute, Manchester, England.
Citation:
The Christie Hospital adjuvant tamoxifen trial. 1992 (11):121-5 J. Natl. Cancer Inst Monographs
Journal:
Journal of the National Cancer Institute Monographs
Issue Date:
1992
URI:
http://hdl.handle.net/10541/109472
PubMed ID:
1627418
Type:
Article
Language:
en
ISSN:
1052-6773
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRibeiro, Gen
dc.contributor.authorSwindell, Ricen
dc.date.accessioned2010-08-11T15:44:51Z-
dc.date.available2010-08-11T15:44:51Z-
dc.date.issued1992-
dc.identifier.citationThe Christie Hospital adjuvant tamoxifen trial. 1992 (11):121-5 J. Natl. Cancer Inst Monographsen
dc.identifier.issn1052-6773-
dc.identifier.pmid1627418-
dc.identifier.urihttp://hdl.handle.net/10541/109472-
dc.description.abstractA clinical trial was carried out at The Christie Hospital, Manchester, England, between November 1976 and June 1982. Following surgery, patients with clinical stage T1-T3a, N1-N2b, M0 tumors were randomly allocated in the following way: premenopausal women to either tamoxifen 20 mg/day for 1 year or to an irradiation-induced menopause; postmenopausal women to either tamoxifen for 1 year or no further treatment (controls). In the node-negative subgroup, an analysis at a median follow-up of 10 years shows no statistically significant difference in overall or disease-free survival between tamoxifen-treated patients and irradiation-induced menopause and control patients. Side effects were few, and compliance was excellent. There was no significant increase of second primary tumors in target endocrine organs in the tamoxifen-treated patients. For the whole series of 961 patients, a log-rank analysis of events, allowing for node status, still shows a statistically significant benefit for tamoxifen-treated patients (P = .04).en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectSecond Primary Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshBreast Neoplasms-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshEngland-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshLymphatic Metastasis-
dc.subject.meshMenopause-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms, Second Primary-
dc.subject.meshOncology Service, Hospital-
dc.subject.meshPostoperative Care-
dc.subject.meshRisk Factors-
dc.subject.meshSurvival Rate-
dc.subject.meshTamoxifen-
dc.titleThe Christie Hospital adjuvant tamoxifen trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiotherapy, Christie Hospital, Holt Radium Institute, Manchester, England.en
dc.identifier.journalJournal of the National Cancer Institute Monographsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.